Cosmo Pharmaceuticals N.V
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesa… Read more
Cosmo Pharmaceuticals N.V (CMOPF) - Total Liabilities
Latest total liabilities as of June 2025: $143.35 Million USD
Based on the latest financial reports, Cosmo Pharmaceuticals N.V (CMOPF) has total liabilities worth $143.35 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Cosmo Pharmaceuticals N.V - Total Liabilities Trend (2004–2024)
This chart illustrates how Cosmo Pharmaceuticals N.V's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Cosmo Pharmaceuticals N.V Competitors by Total Liabilities
The table below lists competitors of Cosmo Pharmaceuticals N.V ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CECEP Techand Ecology&Environment Co Ltd
SHE:300197
|
China | CN¥23.65 Billion |
|
Bergman & Beving AB (publ)
ST:BERG-B
|
Sweden | Skr4.41 Billion |
|
Zhejiang Dayuan Pumps Ind Co
SHG:603757
|
China | CN¥847.01 Million |
|
Shenzhen Urovo Technology Co Ltd
SHE:300531
|
China | CN¥720.47 Million |
|
Tianjin Jingwei Electric Wire Co Ltd
SHE:300120
|
China | CN¥1.65 Billion |
|
Forum Energy Technologies Inc
NYSE:FET
|
USA | $472.78 Million |
|
Hertz Global Holdings Inc
NASDAQ:HTZ
|
USA | $22.77 Billion |
|
VBG Group AB (publ)
ST:VBG-B
|
Sweden | Skr3.11 Billion |
Liability Composition Analysis (2004–2024)
This chart breaks down Cosmo Pharmaceuticals N.V's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cosmo Pharmaceuticals N.V's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cosmo Pharmaceuticals N.V (2004–2024)
The table below shows the annual total liabilities of Cosmo Pharmaceuticals N.V from 2004 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $141.68 Million | +13.40% |
| 2023-12-31 | $124.94 Million | -57.76% |
| 2022-12-31 | $295.80 Million | +1.00% |
| 2021-12-31 | $292.88 Million | +49.40% |
| 2020-12-31 | $196.04 Million | +2.41% |
| 2019-12-31 | $191.43 Million | +5.86% |
| 2018-12-31 | $180.83 Million | +549.14% |
| 2017-12-31 | $27.86 Million | -0.21% |
| 2016-12-31 | $27.92 Million | -18.60% |
| 2015-12-31 | $34.30 Million | -53.23% |
| 2014-12-31 | $73.33 Million | +220.94% |
| 2013-12-31 | $22.85 Million | -16.13% |
| 2012-12-31 | $27.24 Million | +86.55% |
| 2011-12-31 | $14.60 Million | -56.35% |
| 2010-12-31 | $33.46 Million | +186.73% |
| 2009-12-31 | $11.67 Million | -19.68% |
| 2008-12-31 | $14.53 Million | +20.26% |
| 2007-12-31 | $12.08 Million | -33.86% |
| 2006-12-31 | $18.27 Million | -33.77% |
| 2005-12-31 | $27.58 Million | +13.30% |
| 2004-12-31 | $24.34 Million | -- |